胃肠道间质瘤治疗的研究进展

Abstract
Figure/Table
References (34)
Related Citation (15)

Download: PDF (579 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. Surgery is the first choice of treatment for patients with localized or potentially resectable GISTs, but patients still have a high recurrence rate after receiving surgical treatment. The emergence of targeted drugs and the progress of surgical methods have made the current treatment of GISTs appear to be minimally invasive, phased, and multidisciplinary, which can better improve the living standards of patients with gastrointestinal stromal tumors. In view of the complexity of the pathogenesis of GISTs and the instability of clinical treatment and prognosis, the treatment of patients with GISTs is now described.

Key words： Gastrointestinal stromal tumors Treatment Research Progress

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CUI Yi1 HAN Zhenguo2

Cite this article:

CUI Yi1 HAN Zhenguo2. Research progress in the treatment of gastrointestinal stromal tumors[J]. 中国医药导报, 2020, 17(1): 42-45.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I1/42

[1] 夏枭，谢阜明，王亚旭.胃肠道间质瘤基因突变类型与靶向治疗研究进展[J].现代医药卫生，2019，35（12）：1827-1830.
[2] Nishida T，Goto O，Raut CP，et al. Diagnostic and strategy for small gastryintestinal stromal tumors [J]. Cancer，2016， 122（20）：3110-3118.
[3] 展鹏远.胃镜联合腹腔镜治疗胃间质瘤安全性与可行性分析[J].淮海医药，2017，35（6）：685-687．
[4] 沈友辉，王东旭.胃肠道间质瘤的研究进展[J].中国城乡企业卫生，2019，34（6）：64-68.
[5] 史良玉，王玉平，任茜，等.胃肠道间质瘤治疗的研究进展[J].医学综述，2017，23（19）：3764-3768.
[6] Kim HH. Endoscopic treatment for gastrointestinal stromal tumor：advantages and hurdles [J]. World J Gastrointest Endosc，2015，7（3）：192-205．
[7] 廖湘祁，唐岸柳，肖定华，等.内镜全层切除术在34例胃固有肌层肿瘤治疗中的应用[J].中南大学学报：医学版，2016，41（3）：282-286.
[8] CSCO胃肠间质瘤专家委员会.中国胃肠间质瘤诊断治疗共识（2013年版）[J].临床肿瘤学杂志，2013，18（11）：1025-1032.
[9] Demetri GD，von Mehren M，Antonescu CR，et al. NCCN task force report：update on the management of patients with gastrointestinal stromal tumors [J]. J Natl Compr Canc Netw，2010，8 Suppl 2：S1-S44．
[10] Badic B，Gancel CH，Thereaux J，et al. Surgical and oncological long termout comes of gastrointestinal stromal tumors（GIST）resection-retrospective cohort study [J]. Int J Surg，2018，53（6）：257-261.
[11] 董锡钧，刘映辉，李署光.腹腔镜手术治疗胃肠间质瘤的临床效果分析[J].中国继续医学教育，2015，7（26）：99-100.
[12] Balde AI，Chen T，Hu Y，et al. Safety analysis of laparoscopic endoscopic cooperative surgery versus endoscopic submucosal dissection for selected gastric gastrointestinal stromal tumors：a propensity score-matched study [J]. Surg Endosc，2017，31（2）：843-851.
[13] 肖惠，吴艳烈.腹腔镜、胃镜联合手术在胃间质瘤临床治疗中的应用[J].临床外科杂志，2017，25（12）：902-904.
[14] Tsujimoto H，Yaguchi Y，Kumano I，et al. Successful gastric submucosal tumor resection using laparoscopic and endoscopic cooperative surgery [J]. World J Surg，2012， 36（2）：327-330.
[15] Nishida T，Blay JY，Hirota S，et al. The standard diagnosis，treatment，and follow-up of gastrointestinal stromal tumors based on guideline [J]. Gastric Cancer，2016，19（1）：3-14．
[16] Ford SJ，Gronchi A. Indications for surgery in advanced /metastatic GIST [J]. Eur J Cancer，2016，63：154-167.
[17] 陶丽莹，刘冰熔.胃肠道间质瘤治疗策略的研究进展[J].胃肠病学和肝病学杂志，2017，26（2）：214-217.
[18] Heinrich MC，Rubin BP，Longley BJ，et al. Biology and genetic aspects of gastrointestinal stromal tumors：KIT activation and cytogenic alterations [J]. Hum Pathol，2002， 33（5）：484-495. DOI：10.1016/S0165-4608（01）00395-8.
[19] Nishida T. Asian consensus guidelines for gastrointestinal stromal tumor：what is the same and what is different from glogal guidelines [J]. Trans Gastroenterol Hepatol，2018，3（6）：1-11.
[20] Balachandran VP，DeMatteo RP. Targeted therapy for cancer：the gastrointestinal stromal tumor model [J]. Surg Oncol Clin North Am，2013，22（4）：805-821.
[21] Ishikawa T，Kanda T，Kametama H，et al. Neoadjuvant therapy for gastrointestinal stromal tumor [J]. Transl Gastrointestinal Hepatol，2018，3（7）：17.
[22] Dematteo RP，Ballman K，Antonescu CR，et al. Adjuvant imatinib mesylate after resection of localised，primary gastrointestinal stromal tumor：a randomised，double-blind，placebo-controlled trial [J]. Lancet，2009，373（9669）：1097-1104.
[23] Valsangkar N，Sehdev A，Misra S，et al． Current management of gastrointestinal stromal tumors [J]. Surgery，2015， 158（5）：1149-1164．
[24] Yoshikawa K，Shimada M，Kurita N，et al. Efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors [J]. Surg Today，2013，43（10）：1162-1167.
[25] Watson GA，Kelly D，Melland-Smith M，et al. Get the GIST An overview of gastrointestinal stromal tumours [J]. Ir J Med Sci，2016，185（2）：319-326．
[26] Raut CP，Espat NJ，Maki RG，et al. Extended treatment with adjuvant imatinib（IM）for patient（pts）with high risk primary gastrointestinal stromal tumors（GIST）：the PERSIST-5 study [J]. J Clin Oncol，2017，35（7）：1516.
[27] The ESMO/European Sarcom a Network Working Group. Gastrointestinal stromal turnouts：ESMO Clinical Practice Guide lines for diagnosis，treatment and follow-up [J]. Ann Oncol，2014，25（Suppl 3）：Ⅲ21-Ⅲ26.
[28] 刘东.c-kit、ETV1、FOXF1的表达与胃肠间质瘤临床病理相关性研究[D].北京：北京协和医学院，2018.
[29] 成驰,孙林德,徐文通.手术治疗伊马替尼耐药后肿瘤局部进展胃肠道间质瘤患者的疗效观察[J].解放军医学院学报，2018，39（11）：944-946，954.
[30] 唐东辰.胃肠道间质瘤临床特征及外科治疗[J].世界最新医学信息文摘，2016，16（56）：26-28.
[31] Schvartsman G，Wagner MJ，Amini B，et al. Treatment partterns，efficacy and toxicity of regorafenib in gastrointestinal stromal tumor patients [J]. Sci Rep，2017，7（1）：17.
[32] Miettinen M，Sobin LH，Lasota J. Gastrointestinal stromal tumors of the stomach：a clinicopathologic，immunohistochemical，and molecular genetic study of 1765 cases with long-term follow-up [J]. Am J Surg Pathol，2005，29（1）：52-68.
[33] Evans EK，Hodous BL，Gardino AK，et al. Abstract 791：BLU-285，the first selective inhibitor of PDGFRαD842V and KIT Exon 17 mutants [J]. Cancer Res，2015，75（15）：791.
[34] Gebreyohannes YK，Zhai ME，Wozniak A，et al. Efficacy of BLU-285，a novel，potent inhibitor of Exon 17 Mutant KIT and PDGFRA D842V，in patient-derived xenograft model of gastrointestinal stromal tumor（GIST） [J]. J Clin Oncol，2016，34（9）：45.